Key result
Andexanet alfa cuts post-TBI hematoma volume ~44% and improves neurological deficits in rivaroxaban-pretreated mice.
Why the study?
To explore the use of andexanet alfa in an experimental model of traumatic brain injury mimicking closed head trauma under rivaroxaban-induced anticoagulation.
Does andexanet alfa reduce hematoma expansion and improve functional outcomes in mice with traumatic brain injury pretreated with rivaroxaban?
Does andexanet alfa reduce hematoma expansion and improve functional outcomes in mice with traumatic brain injury pretreated with rivaroxaban?
In a preclinical mouse model of traumatic brain injury under rivaroxaban anticoagulation, andexanet alfa successfully reduced hematoma expansion and improved subacute functional outcomes.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in rivaroxaban-associated TBI; hypothesis-generating for andexanet alfa pending clinical trials.
Objective With the introduction of andexanet alfa, a specific antidote is now available to address life-threatening bleeding associated with factor Xa inhibitors. In this study, we explore its use in an experimental model of traumatic brain injury (TBI), mimicking a closed head trauma under rivaroxaban-induced anticoagulation. Methods Male C57BL6 mice were fed with rivaroxaban (10 mg/kg body weight). Subsequently, TBI was induced by controlled cortical impact (CCI) and andexanet alfa or placebo were administered as intravenous bolus injections. Edema and hemorrhage volume was quantified by magnetic resonance imaging (MRI) 24 h and 7 days after CCI. Functional outcome was assessed at day 1, 3, and 7 thereafter. Results Andexanet alfa led to reduced hemorrhage volume 24 h and 7 days after CCI as compared with control group without reversal of anticoagulation (2.9 ± 1.4 µl vs. 5.2 ± 3.3 µl, p = 0.02; 3.4 µl ± 1.5 µl vs. 5.5 µl ± 2.4 µl, p = 0.04). Along with the smaller hematoma sizes in the MRI, edema volume was significantly lower in mice treated with andexanet alfa 24 h and 7 days after CCI (−6.3% of contralateral hemisphere, p = 0.0002; and −7.1% of contralateral hemisphere, p = 0.006). While functional outcomes did not differ at 24 h following TBI, andexanet alfa improved neurological deficits after 7 days. Conclusions Our experimental data suggests that the use of andexanet alfa improves functional outcomes by reduction of factor Xa inhibitor–associated hematoma expansion in the subacute phase following TBI.
No takes yet. Share an insight, caveat, or question.
Lieschke et al. (2026) studied Male C57BL6/J mice aged 8–12 weeks pretreated with rivaroxaban anticoagulation undergoing moderate controlled cortical impact traumatic brain injury (n=60). Andexanet alfa vs. Placebo (phosphate-buffered saline 5 ml/kg intravenous bolus 30 minutes post-injury) was evaluated on Hematoma volume measured by post-mortem MRI at 24 hours and 7 days post controlled cortical impact (p=0.02 at 24 hours, p=0.02). Andexanet alfa reduced hematoma volume from 5.2 ± 3.3 µl to 2.9 ± 1.4 µl at 24 hours and improved neurological deficits at 7 days post-TBI in rivaroxaban-pretreated mice.
Synapse has enriched 10 related papers. Consider them for comparative context: